Keyphrases
Ashkenazi Jews
16%
BRCA Carriers
16%
BRCA mutation
50%
BRCA mutation Carriers
16%
Breast Cancer Risk
16%
Cancer Prevention
100%
Carrier State
33%
Cost-effectiveness
100%
Cost-effectiveness Analysis
16%
Decision-analytic Model
16%
Discount Rate
16%
Female Population
16%
General Health
33%
Genetic Screening
100%
Health Screening
33%
Incremental Cost-effectiveness Ratio
16%
Influential Parameters
16%
Insurance Providers
33%
Israel
100%
Israeli
50%
Life-years Gained
16%
Lifetime Cost
16%
Markovian Process
16%
Medical Insurance
33%
Ministry of Health
16%
Model Uncertainty
16%
Mutation Screening
16%
Ovarian Cancer Risk
16%
Population Screening
50%
Prevalence Rate
50%
Process Decision
16%
Published Data
16%
Quality-adjusted Life Years
33%
Risk Reduction
16%
Salpingo-oophorectomy
16%
Screening Cost
16%
Screening for Cancer
100%
Screening Strategy
33%
Sensitivity Analysis
16%
Shekel
33%
Treatment-related
16%
Whole Population
100%
Medicine and Dentistry
BRCA Mutation
66%
Breast Cancer
16%
Cancer Prevention
100%
Cancer Risk
16%
Cost-Effectiveness Analysis
100%
Decision Making
16%
Genetic Screening
100%
Health Care Cost
100%
Heterozygote
33%
Lifespan
16%
Mass Screening
83%
Ovarian Cancer
16%
Prevalence
100%
Quality Adjusted Life Year
33%
Risk Reduction
16%
Salpingooophorectomy
16%
Biochemistry, Genetics and Molecular Biology
Decision Making
16%
Genetic Carrier
33%
Genetic Screening
100%
Heterozygote
33%
Lifespan
16%
Mass Screening
83%
Prevalence
100%
Quality Adjusted Life Year
33%
Risk Reduction
16%
Immunology and Microbiology
Decision Making
16%
Genetic Screening
100%
Heterozygote
33%
Lifespan
16%
Mass Screening
83%
Prevalence
100%
Quality Adjusted Life Year
33%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
16%
Malignant Neoplasm
100%
Ovary Cancer
16%
Prevalence
100%